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Recognised by their de novo expression of alpha-smooth muscle actin (SMA), recruitment of myofibroblasts is key to the
pathogenesis of fibrosis in chronic kidney disease. Increasingly, we realise that epithelial-mesenchymal transition (EMT) may
be an important source of these cells. In this study we describe a novel model of renal EMT. Rat kidney explants were finely
diced on gelatin-coated Petri dishes and cultured in serum-supplemented media. Morphology and immunocytochemistry were
used to identify mesenchymal (vimentin+, α-smooth muscle actin (SMA)+, desmin+), epithelial (cytokeratin+), and endothelial
(RECA+) cells at various time points. Cell outgrowths were all epithelial in origin (cytokeratin+) at day 3. By day 10, 50± 12%
(mean± SE) of cytokeratin+ cells double-labelled for SMA, indicating EMT. Lectin staining established a proximal tubule origin.
By day 17, cultures consisted only of myofibroblasts (SMA+/cytokeratin−). Explanting is a reproducible ex vivo model of EMT. The
ability to modify this change in phenotype provides a useful tool to study the regulation andmechanisms of renal tubulointerstitial
fibrosis.
1. Introduction
Over recent years, considerable clinical and laboratory work
has focused on the role of tubulointerstitial pathology in
progressive renal disease and the cellular basis of its patho-
genesis [1, 2].
Many of these studies have now indicated that interstitial
fibroblasts are a major determinant of progression of all hu-
man and experimental models of end-stage renal disease.
Fibroblasts can be stimulated by a wide variety of agents de-
rived from stimulated tubular cells, leukocytes, or from the
fibroblasts themselves. Activated fibroblasts, the so-called
myofibroblasts, are usually recognized by their de novo
expression of alpha-smooth muscle actin (SMA), a protein
usually only found in vascular smooth muscle cells [3, 4].
Fibroblasts are fundamentally important to the pathogenesis
of tubulointerstitial fibrosis, with animal studies showing
that incorporation of a suicide transgene can conditionally
minimise fibrogenesis through depletion of fibroblasts [5].
It is in turn increasingly recognised that myofibroblasts
may be derived from a number of sources, including resident
fibroblasts, migrating perivascular (adventitial cells), recruit-
ment of circulating progenitor cells, and injured tubular
cells through a process of epithelial mesenchymal transition
(EMT). EMT can be defined as the acquisition of phenotypic
as well as functional properties of mesenchymal cells by
epithelial cells [6]. In this process, epithelial cells lose their
phenotypic markers and characteristics and migrate into the
surrounding matrix where they acquire phenotypic charac-
teristics typical of mesenchymal cells. In vivo models have
shown that EMT is an orchestrated sequence of events
which relies not only on an interplay of different cytokine
and noncytokine mediators but also on the integrity of the
tubular epithelial cell, its intact basement membrane and cell
adhesive proteins, and the nearby interstitium [7]. The re-
peated observation of EMT in both human renal biopsies [8]
and animal models [9] has suggested that tubular epithelial
2 Journal of Biomedicine and Biotechnology
Table 1: Cytochemical markers of renal cell phenotype.
Antigen Supplier Clone Source Specificity
Vimentin Dako V9 Mouse Mesenchymal cells
αSMA Dako 1A4 Mouse Smooth muscle cells, myofibroblasts, mesangial cells
αSMA (Cy3 conjugate) Sigma IA4 Mouse Smooth muscle cells, myofibroblasts, mesangial cells
Desmin Dako D33 Mouse Myofibroblasts, smooth muscle cells, glomerular podocytes
Cytokeratin Dako LP34 Mouse Epithelial cells
RECA Serotec HIS 52 Mouse Endothelial cells
E-cadherin BD Biosciences 36 Mouse Epithelial cells
cells are a major source of interstitial myofibroblasts in the
kidney. Indeed, elegant experiments from Iwano et al. [7]
have shown that after unilateral ureteric obstruction (UUO)
approximately 40% of fibroblasts are derived from EMT. This
suggests that a process that was once thought to be confined
to embryogenesis may in hindsight be a fundamentally
important process in the pathogenesis of renal scarring.
However, the role of EMT in renal fibrosis is not without
controversy [10], which has recently culminated in back-
to-back editorial debate [11]. Recent lineage tracing studies
from Humphreys and colleagues [12] have shown that per-
icytes, not tubule cells, are the predominant source of
fibroblasts in UUO.
Consequently, the study of renal tubulointerstitial fibro-
sis requires robust experimental models that accurately
reproduce EMT in experimental conditions. While most in
vivo models have proven invaluable to delineating mech-
anisms of EMT, the kinetics of EMT has limited their
usefulness. In reality, few cells undergo this process at any one
time in vivo. Likewise, although EMT can be readily induced
in vitro, this is at least in one case quite different from what
happens to the same cells in vivo [12]. Furthermore, the
complexity of EMT and its dependence on other cellular
programmes [13] and the microenvironment [14] raises
important questions about the usefulness of isolated cell
lines.
In this paper we describe the characterisation and vali-
dation of a new ex vivo model of EMT. It is our contention
that this provides an accurate and reproducible model for the
study of this important process.
2. Materials and Methods
2.1. Ex Vivo Culture of Renal Explants. EMT was studied
using cell explant outgrowths from normal rat kidneys using
explanting methods described previously [15]. Renal cortex
for explants was excised from Sprague-Dawley rats asphyxi-
ated with an 80% : 20% mixture of CO2 : O2. Tissue was col-
lected in ice-cold Hanks’ salt solution with gentamycin (MP
Biomedicals, Solon, Ohio, USA). Cultures were established
by dicing cortical tissue onto gelatin- (Sigma, St. Louis, Mo,
USA) coated Petri dishes and covering with DMEM (CSL,
Parkville, Vic, Australia) supplemented with 20% foetal calf
serum (FCS; CSL) and Penicillin/Streptomycin antibiotics
(ICN). Tissue was maintained at 37◦C overnight with fur-
ther medium supplementation the following day. Explant
outgrowths were then cultured for 3–17 days, with medium
changed every third day. In each case cells were fixed by
flooding Petri dishes with ice-cold methanol for 10min.
2.2. Cell Phenotype. Cell outgrowths were phenotyped
by immunocytochemistry, using standard techniques [16].
Fixed cells were consecutively incubated with primary antis-
era against cell-specific proteins using vimentin, SMA, pan-
cytokeratin (all Dako, Glostrup, Denmark), rat endothelial
cell antigen (RECA; Serotec, Oxford, UK), or E-cadherin (BD
Biosciences Pharmingen, San Jose, Calif, USA) (Table 1).
Explants were then rinsed in PBS, incubated with appropri-
ate species-specific biotinylated secondary antisera (Vector
Laboratories, Burlingame, Calif, USA), washed in PBS, and
incubated with avidin-biotin complex (ABC; Vector) and
diaminobenzidine (DAB; Dako). DAB enhancing solution
(Vector) was used to enhance the reaction product, and
cells were then counterstained with Harris haematoxylin and
mounted with Gurr Aquamount (BDH, Poole, UK). Cells
with positive staining were enumerated and expressed as a
percentage of total cells counted.
2.3. Double Labelling of Epithelial and Mesenchymal Cells.
In the case of double labelling, cells were prepared, treated,
and fixed as above. Cells were then washed in PBS, blocked
with normal serum, and incubated with a murine antibody
against anticytokeratin. An anti-mouse FITC (Dako) was
then applied followed by an anti-SMA Cy3 conjugate (Sig-
ma). Cells weremounted in aqueousmountingmedia (Dako)
and viewed with a fluorescent microscope (Leica Microsys-
tems, Wetzlar, Germany) using appropriate filters for 520 nm
(FITC) and 570 nm (Cy3) emissions. Representative images
at the two different wavelengths were captured with a digital
microscope camera (DP10, Olympus, Tokyo, Japan) and
merged using the combine function in PaintShop Pro (Jasc
Software, Minnetonka, Mich, USA).
2.4. Lectin Staining. Explant outgrowths were stained with
lectins to determine the origin of the epithelial cell out-
growths. This methodology has been used previously in a
number of studies to identify epithelial tubular segments
[17–19].
Specificity of lectin binding was first confirmed by stain-
ing normal paraffin-embedded kidney tissue sections. Tissue
sections were incubated for 2 hr with biotin-conjugated
phaseolus vulgaris leukoagglutinin (Pha-L; Vector) (proximal
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Figure 1: Phase contrast light microscopy of tissue at 3, 10, and 17 days after explanting. (a) Cuboidal-shaped cells are clearly seen
propagating from explanted tissue at day 3. (b) By day 10 cells at the periphery have a more elongated morphology (arrows). (c) At day
17, confluent areas of cells form fingerprint patterns, characteristic of fibroblast culture. Diagonal line shows scratch in Petri dish used to
mince tissue and anchor tissue to culture surface. Scale bar = 25 μm.
tubules and thick loop of Henle), phaseolus vulgaris eryth-
roagglutinin (Pha-E; Vector) (proximal tubules), Bandeiraea
simplicifolia I (BSL-I; Sigma) (collecting ducts, vasa recta),
or Arachis hypogaea (Sigma) (distal convoluted tubules and
collecting ducts). This was followed by incubation with ABC
and DAB. Finally, tissue sections were dehydrated, counter-
stained with Harris haematoxylin, and mounted with Gurr
Aquamount.
Likewise, to characterise explant outgrowths, explants
were fixed in methanol at day 10, washed in PBS, and in-
cubated with Pha-L, BSL-I, or AH conjugates before being
treated as above.
2.5. Statistical Analysis. Data is represented as mean ± SE.
3. Results
The basis for presenting this ex vivo model of EMT lies in
the typical growth patterns that have been observed during
explanting of the renal cortex. Once cortical renal tissue is
minced into gelatin-coated Petri dishes, it takes approximate-
ly 3 days before cell growth can be identified. Of those cells
that grow out initially, most are cuboidal in shape (Figure
1(a)). Typical of epithelial cell culture, they grew in a uni-
form manner consistent with being tightly bound by cell-cell
junctions and adhesions [20]. In contrast with this epithelial
cell-like phenotype, from day 10, cells at the periphery of
this outgrowth had a spindle shape appearance and were less
organized in the surrounding matrix (Figure 1(b)). This was
more consistent with a mesenchymal phenotype, their non-
uniformity and weak cellular adhesion sites being indicative
of a migratory capacity [20]. Cells proliferated rapidly over
the next 1-2 weeks until most regions became confluent
(Figure 1(c)).
3.1. Phenotype of Cells Grown from Tissue Explants. To char-
acterise the cells that grow out of explant tissue, cells were
stained with a panel of phenotype markers (Table 1). These
included cytoskeletal proteins (vimentin, SMA, desmin),
RECA, pan-cytokeratin, and the epithelial cell-cell junction
protein E-cadherin. In accordance with the staining char-
acteristics, cells were defined as mesenchymal (vimentin+,
SMA+, desmin+), epithelial (cytokeratin+), or endothelial
(RECA+) cells. At day 7, 66 ± 9% (mean ± SE) of cells
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Figure 2: Immunohistochemical staining characteristics of cells 10 days after explanting. Two distinct areas are seen—an inner most area of
cuboidal-shaped cells staining for (a) cytokeratin and (b) E-cadherin (black asterisk) and stellate-shaped cells at the periphery staining for
(c) the myofibroblast marker SMA. Occasional cells at the junction of the two areas stain for SMA (arrow heads). (d) All cells were negative
for the endothelial marker RECA. Remnants of the tissue explant from which cells have propagated can be seen (white asterisk). Scale bar =
50 μm.
were vimentin+, 21 ± 8% SMA+, 26 ± 8% desmin+, and
79 ± 5% cytokeratin+. Cells did not express RECA. By day
10, explants typically contained clusters of E-cadherin and
cytokeratin-positive cells, surrounded by a peripheral region
of cells staining for the mesenchymal marker SMA (Figure
2). Accordingly, it was apparent that explants consisted of
epithelial cell outgrowths, with myofibroblasts present at the
periphery. The acquisition of SMA, a myofibroblast marker,
at the periphery of the outgrowths suggests that cells that
previously expressed epithelial markers may be undergoing
transition to a mesenchymal cell type.
3.2. Double Labeling Indicates That Cell Outgrowths from
Explants Undergo Progressive EMT. To determine if the mes-
enchymal and epithelial cells shown in Figure 2 were autono-
mous cell populations or cells undergoing EMT, immunoflu-
orescent double labelling was performed at 3, 10, and 17 days
after explanting using red (SMA) and green (cytokeratin)
fluorochromes (Figure 3). Merged fluorescent micrographs
confirmed that at day 3 outgrowths from tissue were
almost exclusively epithelial cells (cytokeratin+/SMA−) with
myofibroblasts (cytokeratin−/SMA+ cells) recognised from
day 10. This was most likely due to EMT as 50± 12% (n = 5
explants) of cytokeratin-positive cells costained for SMA at
day 10. By day 17 cultures were all uniformly myofibroblasts,
each with a well-organised SMA cytoskeleton.
3.3. Lectin Staining Indicates That Cell Outgrowths from
Explants Have a Predominantly Proximal Tubular Derivation.
Little is known about the specific derivation of tubular
epithelial cells during EMT. In attempt to determine the
nephron origin of the cells undergoing EMT, cell explant
outgrowths were labelled for sugar moieties expressed by
various nephron segments. AH is specific for distal tubule
epithelium, whilst Pha-E and Pha-L are specific for proximal
tubule epithelium (data not shown). Staining of explants
with biotinylated lectins illustrates that, of those cells that
grow out of explant tissue, the majority are derived from
proximal tubular epithelium (Figure 4) with no cells staining
positive for distal tubular epithelium lectin markers.
4. Discussion
This study has shown that explanting of renal kidney
tissue is a reproducible ex vivo model of EMT. Explanting
methodologies consistently produced a population of cells
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Figure 3: Double labeling for the epithelial marker cytokeratin and the myofibroblast marker SMA was used to determine if cell outgrowths
were undergoing EMT. Two-colour immunofluorescence was performed at 3, 10, and 17 days after explanting. By labelling for both SMA
(red) and cytokeratin (green), outgrowths were initially epithelial at day 3. By day 10 cell outgrowths expressed both SMA and cytokeratin
(yellow) indicating that cells were coexpressing epithelial and mesenchymal markers. By day 17, cells had developed a mesenchymal
phenotype, and all stained positive for SMA. Scale bar = 25 μm.
displaying the transitional features of EMT. Lectin studies
suggest that the majority of these cells are derived from
proximal tubule segments.
During embryogenesis, EMT gives rise to an array of fully
differentiated adult cell types derived from pluripotential
cells present in the developing embryo [21]. Accordingly,
EMT in the kidney can be viewed as a reversal of renal em-
bryogenesis where the metanephric mesoderm gives rise to
the majority of nephron segments [22]. In the adult such
transitions have generally been confined to those seen in
wound healing and angiogenesis [21]. An increasing amount
of evidence, however, suggests that cellular plasticity in the
adult has been underestimated. Embryonic EMT can be re-
capitulated during certain adult disease states such as cancer
and fibrosis [13] where dramatic morphological and func-
tional changes are required to allow cells to migrate and in-
vade.
Although the importance of EMT in the kidney has only
been recognised relatively recently, the potential for EMT in
adult cell types has been long known [23] and may be a
relatively ubiquitous phenomenon in many labile cell types.
EMT of tubular epithelia is the direct consequence of the
release of a plethora of growth factors and other mediators
in the surrounding environment after injury. These origi-
nate from both resident and infiltrating cells [7]. EMT is
facilitated by the sequential loss of epithelial cell adhesion
[24], degradation of basement membrane, de novo SMA ex-
pression, and migration into the interstitial space [21, 25]. In
fibrotic kidney disease, this culminates in increased deposi-
tion of extracellular matrix and a consequent destruction of
renal architecture and loss of function [4, 21].
In vitro experiments that have been used to demonstrate
EMT to date have provided valuable insights into various
mechanisms governing EMT and have highlighted the com-
plexity in bringing about a complete change in cellular phe-
notype and function. However, although they are able to
provide more steadfast evidence of the sequential events
involved, in vitro experiments typically use immortalised cell
lines or isolated cells in which the relationship between the
tubular epithelium and surrounding matrix environment,
one of which is integral to EMT, cannot be studied [13, 14].
Our work was therefore aimed at taking a more pathophysio-
logically relevant approach to examine the potential of EMT
to occur under ex vivo circumstances.
The explant model described here resembles the sponta-
neous EMT that has been shown to occur with other tissue
explants, in particular the cornea [26]. Initial outgrowths are
cytokeratin positive with cells then changing their phenotype
as they grow outward from the tissue fragments. The fact
that only peripheral cells undergo EMT is consistent with
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Figure 4: Lectin staining characteristics of cell outgrowths, 10 days after explanting. The majority of cells stain for Pha-E and Pha-L,
lectins specific for the proximal tubular epithelium. (a) Arachis hypogaea (AH); (b) Bandeiraea simplicifolia I (BSL-I); (c) Phaseolus vulgaris
erythroagglutinin (Pha-E); (d) Phaseolus vulgaris leukoagglutinin (Pha-L). Scale bar = 25 μm.
Masszi et al.’s postulate that injury or absence of intracellular
contact is a key priming factor for EMT [27, 28]. As indicated
by our results, cells subsequently lose their staining for
cytokeratin and express SMA only. To confirm that these
cells were not autonomous cell populations but rather that
these cells were once epithelial in phenotype, double labelling
was used. This demonstrated that 50% of cells in the pop-
ulation coexpressed SMA and cytokeratin. Although this
study only provides a snapshot of EMT at one given time
point, it supports previous evidence of EMT’s important
contribution to renal fibrogenesis [7].
Several tubule segments have been shown to give rise to
myofibroblasts [29–32], with our study supporting a prox-
imal tubule origin for myofibroblasts. However, given that
we specifically excised renal cortex for explanting, the contri-
bution of other nephron segments to EMT cannot clearly be
determined.
In conclusion, our study highlights that explanting of
normal rat renal tissue is a useful ex vivo model to study EMT.
Given the significance of EMT in the pathogenesis of end-
stage renal disease, this model is a valuable tool for the study
of this important process.
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